Aug 7 |
Incyte's (NASDAQ:INCY) Weak Earnings May Only Reveal A Part Of The Whole Picture
|
Aug 1 |
Incyte Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
Jul 30 |
Incyte drops 5 clinical drug candidates following a strategic review
|
Jul 30 |
Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance
|
Jul 30 |
Incyte Corporation (INCY) Q2 2024 Earnings Call Transcript
|
Jul 30 |
Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top
|
Jul 30 |
Incyte (INCY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
|
Jul 30 |
Incyte Corporation 2024 Q2 - Results - Earnings Call Presentation
|
Jul 30 |
Incyte (INCY) Reports Q2 Loss, Tops Revenue Estimates
|
Jul 30 |
Incyte trims cancer drug pipeline in R&D refocus
|